PolypDx™ for Clinicians.

PolypDx™ was developed and validated in a large-scale (nearly 1000-patient) clinical trial in Alberta, Canada in conjunction with University of Alberta, the Edmonton Colon Cancer Screening Program (Scope), and Alberta Health Services (formerly, Capital Health).

PolypDx™ is currently available as a laboratory-developed test through a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory in the U.S.

The science behind the test.

PolypDx™ is a metabolomics-based screening test designed for high-throughput screening, using Liquid Chromatography–Mass Spectrometry (LC-MS) technology.

PolypDx™ is based on the analysis of key metabolomic biomarkers in urine. The biomarker measurement data are interpreted by a proprietary algorithm which generates the PolypDx™ test result.

STEP ONE:

COLLECT URINE SAMPLE AND SHIP TO TESTING FACILITY.

STEP TWO:

SAMPLES ARE PREPARED FOR Liquid Chromatography-Mass Spectrum Technology TESTING.

STEP THREE:

TESTING ANALYZES METABOLOMIC BIOMARKERS.

STEP FOUR:

RESULTS ARE RETURNED TO PRESCRIBING DOCTOR.

STEP FIVE:

RESULTS CONFIRMED AND RELAYED TO PATIENT.

Interpreting the results.

A positive result would indicate the patient is likely to have a polyp and further investigation, such as a follow up with a colonoscopy, is strongly recommended.

A negative result would indicate the patient is less likely to have a polyp. Patients may still require further investigation, regular interval surveillance for polyp detection is recommended.